3 Jun 2020 11:52
UK TRADING UPDATE SUMMARY: Integumen Kicks Off Covid-19 Skin Trials
UK TRADING UPDATE SUMMARY: Integumen Kicks Off Covid-19 Skin Trials
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
AMYT.L Share News (AMYT)
AMYT Share
Price
AMYT Share
News
AMYT Share
Chat
AMYT Share
Trades
AMYT
Live RNS
AMYT Share
Charts
AMYT Broker
Ratings
AMYT Directors
Deals
AMYT Financial
Diary
AMYT
Fundamentals
AMYT Short
Positions
AMYT
Media
AMYT.L Information
- There is currently no data for AMYT
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.11 May 2020 12:19
Amryt Pharma Cheers Strong 2019 And Beats Expectations So Far In 2020
Amryt Pharma Cheers Strong 2019 And Beats Expectations So Far In 2020
Read more23 Apr 2020 15:40
UK TRADING UPDATE SUMMARY: Braemar Says Oil Tankers Wanted For Storage
UK TRADING UPDATE SUMMARY: Braemar Says Oil Tankers Wanted For Storage
Read more23 Mar 2020 19:01
Amryt Pharma Financially Strong, Revenue Rises More Double Digits
Amryt Pharma Financially Strong, Revenue Rises More Double Digits
Read more19 Dec 2019 14:13
Amryt Pharma Shares Rise As It Cheers Aegerion Acquisition Synergies
Amryt Pharma Shares Rise As It Cheers Aegerion Acquisition Synergies
Read more5 Nov 2019 11:09
Amryt Pharma upbeat on progress in first nine months of year
(Sharecast News) - Amryt Pharma updated the market on its trading update for the nine months ended 30 September on Tuesday, noting that it had completed the transaction to acquire Aegerion Pharmaceuticals on 24 September.
Read more5 Nov 2019 10:23
Amryt Pharma Revenue Rises On Performance From Two New Assets
Amryt Pharma Revenue Rises On Performance From Two New Assets
Read more1 Oct 2019 18:49
Amryt Pharma Skin Condition Drug Gets US FDA Fast Track Designation
Amryt Pharma Skin Condition Drug Gets US FDA Fast Track Designation
Read more1 Oct 2019 15:08
Amryt gets FDA fast track for Oleogel-S10
(Sharecast News) - Biopharmaceutical company Amryt Pharma announced on Tuesday that the US Food and Drug Administration (FDA) has designated the investigation of 'AP101' - Oleogel-S10 - for the treatment of epidermolysis bullosa (EB) as a 'Fast Track' development programme.
Read more30 Sep 2019 18:49
Amryt Pharma Loss Widens On Aegerion Deal Costs; Lojuxta Revenue Rises
Amryt Pharma Loss Widens On Aegerion Deal Costs; Lojuxta Revenue Rises
Read more25 Sep 2019 12:24
Amryt Pharma Completes Combination With Aegerion Pharmaceuticals
Amryt Pharma Completes Combination With Aegerion Pharmaceuticals
Read more24 Sep 2019 15:00
Amryt Pharma Shares Temporarily Suspended On Aegerion Buy
Amryt Pharma Shares Temporarily Suspended On Aegerion Buy
Read more21 May 2019 12:35
Amryt Pharma Agrees To All-Paper Acquisition Of Aegerion (ALLISS)
LONDON (Alliance News) - Amryt Pharma PLC on Tuesday said it has agreed the all-paper acquisition of Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics Inc, and intends to raise USD60
Read more17 Apr 2019 11:17
Amryt Pharma Loss Narrows On Revenue From Cholesterol Drug Lojuxta
LONDON (Alliance News) - Amryt Pharma PLC on Wednesday said its annual loss narrowed as a result of increased revenue from its drug Lojuxta.The company's pretax loss shrank to EUR25.7
Read more28 Feb 2019 14:39
Amryt gets approval to extend EASE trial to infants and children
(Sharecast News) - Orphan drug company Amryt Pharma updated the market on its phase 3 'EASE' trial for AP101 as a potential treatment for epidermolysis bullosa (EB) on Thursday, reporting that following an assessment by the trial's independent data monitoring committee, it could now enrol infants and children with EB between the ages of 21 days to four years in the trial.
Read more